Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.51 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.51 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | UBE2N | P61088 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | F10 | P00742 | 3/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | F2 | P00734 | 1/20 | 0.43 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5563846 | 0.93 | NR1H4 (0.55) | HDAC8HDAC1HDAC6SMN1; SMN2LMNA | |
| SCHEMBL5568380 | 0.92 | ROCK2 (0.47) | HDAC8HDAC1HDAC6NR1H4F10 | |
| SCHEMBL5568563 | 0.92 | NPC1 (0.53) | HDAC8HDAC1HDAC6SMN1; SMN2LMNA | |
| SCHEMBL5568105 | 0.90 | NPC1 (0.48) | HDAC8HDAC1HDAC6SMN1; SMN2LMNA | |
| SCHEMBL5567376 | 0.89 | MEN1 (0.51) | HDAC1SMN1; SMN2LMNAMAPTNPC1 | |
| SCHEMBL5568303 | 0.88 | F10 (0.43) | HDAC8HDAC1HDAC6SMN1; SMN2LMNA | |
| SCHEMBL5054227 | 0.88 | RXFP1 (0.46) | HDAC1SMN1; SMN2MAPTNR1H4F10 | |
| SCHEMBL5568503 | 0.88 | MEN1 (0.48) | HDAC1SMN1; SMN2LMNAHPGDMAPT | |
| SCHEMBL5564310 | 0.88 | HDAC1 (0.52) | HDAC8HDAC1HDAC6SMN1; SMN2LMNA | |
| SCHEMBL5567693 | 0.87 | MAPT (0.47) | HDAC1SMN1; SMN2LMNAHPGDMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7247654-B2 | 3,4-disubstituted benzamidines and benzylamines, and analogues thereof, useful as serine protease inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-07-24 | — | — | US | claimed |
| EP-1628947-A2 | 3,4-DISUBSTITUTED BENZAMIDINES AND BENZYLAMINES, AND ANALOGUES THEREOF, USEFUL AS SERINE PROTEASE INHIBITORS | Bristol-Myers Squibb Company (US) | 2006-03-01 | — | — | EP | claimed |
| US-20050009895-A1 | 3,4-disubstituted benzamidines and benzylamines, and analogues thereof, useful as serine protease inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2005-01-13 | — | — | US | claimed |
| WO-2004110374-A2 | 3,4-DISUBSTITUTED BENZAMIDINES AND BENZYLAMINES, AND ANALOGUES THEREOF, USEFUL AS SERINE PROTEASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-12-23 | — | — | WO | claimed |
| US-7247654-B2 | 3,4-disubstituted benzamidines and benzylamines, and analogues thereof, useful as serine protease inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-07-24 | — | — | US | disclosed |
| EP-1628947-A2 | 3,4-DISUBSTITUTED BENZAMIDINES AND BENZYLAMINES, AND ANALOGUES THEREOF, USEFUL AS SERINE PROTEASE INHIBITORS | Bristol-Myers Squibb Company (US) | 2006-03-01 | — | — | EP | disclosed |
| US-20050009895-A1 | 3,4-disubstituted benzamidines and benzylamines, and analogues thereof, useful as serine protease inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2005-01-13 | — | — | US | disclosed |
| WO-2004110374-A2 | 3,4-DISUBSTITUTED BENZAMIDINES AND BENZYLAMINES, AND ANALOGUES THEREOF, USEFUL AS SERINE PROTEASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050009895-A1 | 3,4-disubstituted benzamidines and benzylamines, and analogues thereof, useful as serine protease inhibitors | TFPI, HABP2, TFPI2 | HDAC8 795/4885HDAC1 1184/4885HDAC6 826/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.